keyword
https://read.qxmd.com/read/38681733/distribution-of-cyp2d6-and-cyp2c19-gene-polymorphisms-in-han-and-uygur-populations-with-breast-cancer-in-xinjiang-china
#1
JOURNAL ARTICLE
Muzhapaer Abudukeremu, Aisikaer Ayoufu, Adila Tuerhong, Xuelaiti Paizula, Jiang-Hua Ou
The aim of this study was to investigate the frequency distribution of the cytochrome P450 ( CYP450 ) enzymes, CYP2D6 and CYP2C19 , and the form of tamoxifen metabolisation in premenopausal patients with breast cancer in the Han and Uygur ethnic groups of Xinjiang to guide rational clinical drug use. A total of 125 Han patients and 121 Uygur patients with premenopausal hormone-receptor-positive breast cancer treated at the Xinjiang Uygur Autonomous Region Cancer Hospital between 1 June 2011 and 1 December 2013 were selected...
2024: Open Life Sciences
https://read.qxmd.com/read/38675148/proton-pump-inhibitors-in-eosinophilic-esophagitis-a-review-focused-on-the-role-of-pharmacogenetics
#2
REVIEW
Leticia Rodríguez-Alcolado, Pilar Navarro, Laura Arias-González, Elena Grueso-Navarro, Alfredo J Lucendo, Emilio J Laserna-Mendieta
Proton-pump inhibitors (PPIs) are the most administered first-line treatment for eosinophilic esophagitis (EoE). However, only around half of EoE patients respond histologically to a double dosage of PPI. In addition, 70% of responders maintain EoE in remission after tapering the PPI dose. In order to avoid endoscopy with biopsies-the only accurate method of assessing PPI response-efforts have been made to identify PPI responder patients. The clinical or endoscopic features and biomarkers evaluated so far, however, have not proven to be sufficient in predicting PPI response...
April 2, 2024: Pharmaceutics
https://read.qxmd.com/read/38671468/genetic-variability-in-stroke-patients-cyp2c19-polymorphisms-unraveled
#3
JOURNAL ARTICLE
Peiyi Peng, Yingxiu Xiao, Xuehong Peng, Jianqiang Chen, Nuan Chen
OBJECTIVE: To study the distribution characteristics of CYP2C19 polymorphisms in patients suffering from stroke in Han Chinese patients. METHOD: PCR and DNA microarray chip technology were used to detect the CYP2C19 genotype of 549 patients with stroke, and the genotype, allele frequency and metabolic type of patients with different sexes, ages and types of infarctions and the independent risk factors for clopidogrel resistance were analyzed. RESULTS: Six genotypes were detected in these 549 patients...
April 26, 2024: BMC Medical Genomics
https://read.qxmd.com/read/38669051/clinician-perspectives-regarding-cyp2c19-genotype-testing-in-patients-with-critical-limb-ischemia-a-delphi-approach
#4
JOURNAL ARTICLE
Christopher Regan, Lindsey E Scierka, Alan Dardik, Britt Tonnessen, Cassius Iyad Ochoa Chaar, Costin Ionescu, Edouard Aboian, Jonathan Cardella, Naiem Nassiri, Raul Guzman, Robert Attaran, Sameer Nagpal, Samit Shah, Kim G Smolderen, Carlos Mena-Hurtado
OBJECTIVES: Antiplatelet therapy is an essential element in the management of patients with arterial vascular disease. In peripheral arterial disease (PAD), dual antiplatelet therapy (DAPT), primarily clopidogrel and aspirin, is routinely prescribed following intervention. There is sparse data regarding the need for DAPT, the appropriate duration, or the heterogeneity of treatment effects for antiplatelet regimens across patients, leading to potential uncertainty and heterogeneity around treatment practices...
April 26, 2024: Vascular
https://read.qxmd.com/read/38654529/impact-of-cyp2c19-cyp2c9-cyp3a4-and-fmo3-genetic-polymorphisms-and-sex-on-the-pharmacokinetics-of-voriconazole-after-single-and-multiple-doses-in-healthy-chinese-subjects
#5
JOURNAL ARTICLE
Shuaibing Liu, Xia Yao, Jun Tao, Shiyu Zhao, Suke Sun, Suyun Wang, Xin Tian
Voriconazole is the first-line treatment for invasive aspergillosis. Its pharmacokinetics exhibit considerable inter- and intra-individual variability. The purpose of this study was to investigate the effects of CYP2C19, CYP2C9, CYP3A4, and FMO3 genetic polymorphisms and sex on the pharmacokinetics of voriconazole in healthy Chinese adults receiving single-dose and multiple-dose voriconazole, to provide a reference for its clinical individualized treatment. A total of 123 healthy adults were enrolled in the study, with 108 individuals and 15 individuals in the single-dose and multiple-dose doses, respectively...
April 23, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38652504/recommendations-for-pharmacogenetic-testing-in-clinical-practice-guidelines-in-the-us
#6
JOURNAL ARTICLE
Daniel L Hertz, Chad A Bousman, Howard L McLeod, Andrew A Monte, Deepak Voora, Lori A Orlando, Rustin D Crutchley, Benjamin Brown, Wrenda Teeple, Sara Rogers, Jai N Patel
DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: Pharmacogenetic testing can identify patients who may benefit from personalized drug treatment...
April 23, 2024: American Journal of Health-system Pharmacy: AJHP
https://read.qxmd.com/read/38640781/investigation-of-smoking-on-the-antiplatelet-response-to-clopidogrel-unravelling-the-smoker-s-paradox
#7
REVIEW
Frank A Plakogiannis, Jakob Weidmann, Blake Fraser, Justin Kwong, Diana Asi, Pratham Kumar, Madeleine Baldock, Jasmine Naamo, Ruhani Baluja, Rachelle Catanzariti, Stewart Yeung, Lisa Pont, Kylie Williams, Gabriele De Rubis, Kamal Dua, Nadeem Irfan Bukhari
The intricate relationship between smoking and the effects of the antiplatelet drug clopidogrel has been termed the "smoker's paradox". This paradox details the enhanced efficacy of clopidogrel in smokers compared to non-smokers. This review begins with an exploration of the proposed mechanisms of the smoker's paradox, particularly drawing attention to the induction of cytochrome P450 (CYP) isoenzymes via tobacco smoke, specifically the enzymes CYP1A2 and CYP2C19. Moreover, an investigation of the effects of genetic variability on the smoker's paradox was undertaken from both clinical and molecular perspectives, delving into the effects of ethnicity and genetic polymorphisms...
April 10, 2024: Pathology, Research and Practice
https://read.qxmd.com/read/38638867/assessment-of-omeprazole-and-famotidine-effects-on-the-pharmacokinetics-of-tacrolimus-in-patients-following-kidney-transplant-randomized-controlled-trial
#8
JOURNAL ARTICLE
Miłosz Miedziaszczyk, Marek Karczewski, Tomasz Grabowski, Anna Wolc, Ilona Idasiak-Piechocka
Tacrolimus is metabolized in the liver with the participation of the CYP3A4 and CYP3A5 enzymes. Proton pump inhibitors are used in kidney transplant patients to prevent duodenal and gastric ulcer disease due to glucocorticoids. Omeprazole, unlike famotidine, is a substrate and inhibitor of the enzymes CYP2C19, CYP3A4, CYP3A5. The aim of this study was to compare the impact of omeprazole and famotidine on the pharmacokinetics of tacrolimus. A randomized, non-blinded study involving 22 stabilized adult kidney transplant patients was conducted...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38637968/phenotype-genotype-correlation-applying-a-cocktail-approach-and-an-exome-chip-analysis-reveals-further-variants-contributing-to-variation-of-drug-metabolism
#9
JOURNAL ARTICLE
Ruwen Böhm, Henrike Bruckmueller, Stefan Oswald, Matthias Hübenthal, Meike Kaehler, Lena Ehmke, Jan Höcker, Werner Siegmund, Andre Franke, Ingolf Cascorbi
Although great progress has been made in the fine-tuning of diplotypes, there is still a need to further improve the predictability of individual phenotypes of pharmacogenetically relevant enzymes. The aim of this study was to analyze the additional contribution of sex and variants identified by exome chip analysis to the metabolic ratio of five probe drugs. A cocktail study applying dextromethorphan, losartan, omeprazole, midazolam, and caffeine was conducted on 200 healthy volunteers. CYP2D6, 2C9, 2C19, 3A4/5, and 1A2 genotypes were analyzed and correlated with metabolic ratios...
April 18, 2024: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38636577/investigation-of-the-drug-drug-interaction-and-incompatibility-mechanism-between-aconitum-carmichaelii-debx-and-pinellia-ternata-thunb-breit
#10
JOURNAL ARTICLE
Minglei Ge, Huizi Ouyang, Ye Shang, Abdulmumin Muhammad Biu, Xiwei Wu, Caixia Li, Fanjiao Zuo, Yameng Zhu, Zixiang Xue, Jia Hao, Jun He
ETHNOPHARMACOLOGICAL RELEVANCE: The combination of Aconitum carmichaelii Debx (Chuanwu, CW) and Pinellia ternata (Thunb.) Breit (Banxia, BX) forms an herbal pair within the eighteen incompatible medicaments (EIM), indicating that BX and CW are incompatible. However, the scientific understanding of this incompatibility mechanism, especially the corresponding drug-drug interaction (DDI), remains complex and unclear. AIM OF THE STUDY: This study aims to explain the DDI and potential incompatibility mechanism between CW and BX based on pharmacokinetics and cocktail approach...
April 16, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/38631139/influence-of-cyp2c19-and-cyp2d6-on-side-effects-of-aripiprazole-and-risperidone-a-systematic-review
#11
REVIEW
Emma de Brabander, Kristian Kleine Schaars, Therese van Amelsvoort, Roos van Westrhenen
Variability in hepatic cytochrome P450 (CYP) enzymes such as 2C19 and 2D6 may influence side-effect and efficacy outcomes for antipsychotics. Aripiprazole and risperidone are two commonly prescribed antipsychotics, metabolized primarily through CYP2D6. Here, we aimed to provide an overview of the effect of CYP2C19 and CYP2D6 on side-effects of aripiprazole and risperidone, and expand on existing literature by critically examining methodological issues associated with pharmacogenetic studies. A PRISMA compliant search of six electronic databases (Pubmed, PsychInfo, Embase, Central, Web of Science, and Google Scholar) identified pharmacogenetic studies on aripiprazole and risperidone...
April 6, 2024: Journal of Psychiatric Research
https://read.qxmd.com/read/38629502/influence-of-novel-cyp2c-haplotype-on-proton-pump-inhibitor-pharmacokinetics-in-children
#12
JOURNAL ARTICLE
Kathryn E Kyler, Andrea Gaedigk, Susan Abdel-Rahman, Vincent S Staggs, Robin E Pearce, Paul Toren, J Steven Leeder, Valentina Shakhnovich
In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has been proposed to be associated with increased CYP2C19 activity. We sought to determine if this CYP2C:TG haplotype resulted in similar alterations in metabolism for proton pump inhibitors, which are primarily metabolized by CYP2C19. In a cohort of 41 children aged 6-21 participating in a PPI pharmacokinetic study, effects of the CYP2C:TG allele were assessed by fitting two linear regression models for each of the six PK outcomes assessed, the second of which accounted for the presence of the CYP2C:TG allele...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38612496/impact-of-stat6-variants-on-the-response-to-proton-pump-inhibitors-and-comorbidities-in-patients-with-eosinophilic-esophagitis
#13
JOURNAL ARTICLE
Paula Soria-Chacartegui, Marcos Navares-Gómez, Francisca Molina-Jiménez, Emilio J Laserna-Mendieta, Laura Arias-González, Pedro Majano, Sergio Casabona, Alfredo J Lucendo, Francisco Abad-Santos, Cecilio Santander, Pablo Zubiaur
Proton pump inhibitors (PPIs) are the first-line drug for eosinophilic esophagitis (EoE), although it is estimated that there is a lack of histological remission in 50% of patients. This research aimed to identify pharmacogenetic biomarkers predictive of PPI effectiveness and to study their association with disease features. Peak eosinophil count (PEC) and the endoscopic reference score (EREFS) were determined before and after an eight-week PPI course in 28 EoE patients. The impact of the signal transducer and activator of transcription 6 ( STAT6 ), CYP2C19 , CYP3A4 , CYP3A5, and ABCB1 genetic variations on baseline PEC and EREFS, their reduction and histological response, and on EoE symptoms and comorbidities was analyzed...
March 26, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38611961/evaluation-of-the-lipophilicity-of-angularly-condensed-diquino-and-quinonaphthothiazines-as-potential-candidates-for-new-drugs
#14
JOURNAL ARTICLE
Daria Klimoszek, Małgorzata Jeleń, Beata Morak-Młodawska, Małgorzata Dołowy
Lipophilicity is one of the most important properties of compounds required to estimate the absorption, distribution, and transport in biological systems, in addition to solubility, stability, and acid-base nature. It is crucial in predicting the ADME profile of bioactive compounds. The study assessed the usefulness of computational and chromatographic methods (thin-layer chromatography in a reversed-phase system, RP-TLC) for estimating the lipophilicity of 21 newly synthesized compounds belonging to diquinothiazines and quinonaphthiazines...
April 8, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38607520/enzalutamide-understanding-and-managing-drug-interactions-to-improve-patient-safety-and-drug-efficacy
#15
REVIEW
Brandon W Lennep, Jesse Mack, Srinivasu Poondru, Elizabeth Hood, Brooke D Looney, Monique Williams, Judeth J Bianco, Alicia K Morgans
Enzalutamide is an oral androgen receptor signaling inhibitor utilized in the treatment of men with prostate cancer. It is a moderate inducer of the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19, and a strong inducer of CYP3A4. It was also shown to be a mild inhibitor of the efflux transporter P-glycoprotein in patients with prostate cancer. Enzalutamide is primarily metabolized by CYP3A4 and CYP2C8. The risk of enzalutamide drug interactions arises primarily when it is coadministered with other drugs that interact with these CYPs, including CYP3A4...
April 12, 2024: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://read.qxmd.com/read/38599832/exploring-clozapine-pharmacokinetics-in-tunisian-schizophrenic-patients-a-population-based-modelling-approach-investigating-the-impact-of-genetic-and-non-genetic-variables
#16
JOURNAL ARTICLE
Khadija Mansour, Nadia Ben Fredj, Helmi Ammar, Haifa Ben Romdhane, Ahmed Mhalla, Amel Chaabane, Zohra Chadli, Karim Aouam
Clozapine is characterized by a large within- and between-patient variability in its pharmacokinetics, attributed to non-genetic and genetic factors. A cross-sectional analysis of clozapine trough concentration (Clz C0) issued from Tunisian schizophrenic patients was collected and analysed using a nonparametric modelling approach. We assessed the impact of demographic covariates (age, weight and sex), patient's habits (smoking status, alcohol and caffeine intake) and the genetic factors (CYP1A2*1C, CYP1A2*1F and CYP2C19*2 polymorphisms) on each pharmacokinetic parameter...
April 10, 2024: Basic & Clinical Pharmacology & Toxicology
https://read.qxmd.com/read/38599713/effectiveness-of-clopidogrel-vs-alternative-p2y-12-inhibitors-based-on-the-abcd-gene-score
#17
JOURNAL ARTICLE
Cameron D Thomas, Francesco Franchi, Joseph S Rossi, Ellen C Keeley, R David Anderson, Amber L Beitelshees, Julio D Duarte, Luis Ortega-Paz, Yan Gong, Richard A Kerensky, Natasha Kulick, Caitrin W McDonough, Anh B Nguyen, Yehua Wang, Marshall Winget, William E Yang, Julie A Johnson, Almut G Winterstein, George A Stouffer, Dominick J Angiolillo, Craig R Lee, Larisa H Cavallari
BACKGROUND: An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but its association with response to alternative therapy remains unclear. OBJECTIVES: The aim of this study was to evaluate the association between ABCD-GENE score and the effectiveness of clopidogrel vs alternative P2Y12 inhibitor (prasugrel or ticagrelor) therapy after percutaneous coronary intervention (PCI)...
April 16, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38597874/prediction-of-acute-hepatotoxicity-with-human-pluripotent-stem-cell-derived-hepatic-organoids
#18
JOURNAL ARTICLE
Hyemin Kim, Sang Kyum Kim, Michael Oelgeschläger, Han-Jin Park
Recent development of hepatic organoids (HOs) derived from human pluripotent stem cells (hPSCs) provides an alternative in vitro model that can mimic the human liver detoxification pathway for drug safety assessment. By recapitulating the high level of maturity and drug-metabolizing capacity of the liver in a three-dimensional organoid culture, HOs may allow researchers to assess drug toxicity and metabolism more accurately than animal models or hepatocellular carcinoma cells. Although this promising potential has contributed to the development of various protocols, only a few protocols are available to generate functional HOs with guaranteed CYP450 enzymatic activity, the key feature driving toxic responses during drug metabolism...
April 2024: Current protocols
https://read.qxmd.com/read/38586400/genetic-polymorphisms-of-cyp2c19-in-ecuadorian-population-an-interethnic-approach
#19
JOURNAL ARTICLE
Alba Alonso Llorente, Josefa Salgado Garrido, Óscar Teijido Hermida, Fabricio González Andrade, Alberto Valiente Martín, Ana Julia Fanlo Villacampa, Jorge Vicente Romero
INTRODUCTION: CYP2C19 is a highly polymorphic gene responsible for metabolizing commonly used drugs. CYP2C19*2,*3 (loss of activity alleles) and *17 (increased activity allele) are the principal alleles included in clinical guidelines, however their prevalence varies among different ethnicities. Ecuadorian population is formed by Mestizos, Afrodescendants and Native Americans and frequency of CYP2C19 alleles could be different among them. The objective of this study was to establish the frequency of these variants in the different populations of Ecuador and to compare them with other populations...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38583809/cyp2c9-cyp3a-and-cyp2c19-metabolize-%C3%AE-9-tetrahydrocannabinol-to-multiple-metabolites-but-the-metabolism-is-affected-by-human-liver-fatty-acid-binding-protein-fabp1
#20
JOURNAL ARTICLE
King Clyde B Yabut, Yue Winnie Wen, Keiann T Simon, Nina Isoherranen
Δ9-tetrahydrocannabinol (THC) is the psychoactive constituent of cannabis. It is cleared predominantly via metabolism. Metabolism to 11-OH-THC by cytochrome P450 (CYP) 2C9 has been proposed as the main clearance pathway of THC, with the estimated fraction metabolized (fm ) about 70 %. The remaining clearance pathways are not well established, and it is unknown how THC is eliminated in individuals with reduced CYP2C9 activity. The goal of this study was to systematically identify the CYP enzymes contributing to THC clearance and characterize the metabolites formed...
April 5, 2024: Biochemical Pharmacology
keyword
keyword
47396
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.